Enliven Therapeutics, Inc.
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. (Nasdaq: ELVN) is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. The company aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies for solid tumors and blood cancers.
- 🔗 Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- 🔗 Enliven Therapeutics - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 Enliven Therapeutics - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares | Enliven Therapeutics
- 🔗 Enliven Completes $460.0 Million Follow-On Offering | Baird
Investors
Key highlights
- Completed $460M upsized public follow-on offering in 2025
- NASDAQ-listed as ELVN with multiple public equity raises exceeding $700M combined
- Developer of small molecule drugs targeting solid tumors and blood cancers
- Backed by 17 institutional investors in pre-IPO rounds
Ask StreetZero about Enliven Therapeutics, Inc.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account